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Abbreviations 
A  area of skin  
ANOVA analysis of variance 
DMSO dimethyl sulfoxide 
FDA U.S. Food & Drug Administration 
HPLC high performance liquid chromatography 
IVPT in vitro skin permeation test 
Jin vitro  average flux of drug into the receptor chamber in vitro over the designated time 
interval 
Jin vivo average flux of drug from the SC into the underlying tissue in vivo over the 
duration of the clearance t 
MCl,23h  mass of drug in the SC at 23 hours in vivo (Clearance for 17 h)  
MR  cumulative mass of drug entering the receptor solution from skin in vitro 
MR,jh  cumulative mass of drug entering the receptor solution after j hours in vitro (j = 6, 
8, 23 and 24 h as designated) 
MS,n  mass of drug in the nth sample vial 
MUp,6h  mass of drug in the SC at 6 hours in vivo (Uptake) 
P Pennsaid® solution 2%  
QR  flow rate of receptor solution in vitro 
Q1 same qualitative composition  
Q2 same quantitative composition 
S Solaraze® gel 3%  
SC stratum corneum 
tn  time between drug application and the end of the nth sampling interval 
TEWL transepidermal water loss 
V Voltaren® gel 1% 
VR  volume of receptor chamber 
VS,n  volume of solution in the nth sample vial 
Δt  duration of the clearance period 
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ABSTRACT  
Assessment of the bioavailability of topically applied drugs designed to act within or beneath the 
skin is a challenging objective.  A number of different, but potentially complementary, techniques 
are under evaluation.  The objective of this work was to evaluate in vitro skin penetration and 
stratum corneum tape-stripping in vivo as tools with which to measure topical diclofenac 
bioavailability from three approved and commercialized products (two gels and one solution).  Drug 
uptake into, and its subsequent clearance from, the stratum corneum of human volunteers was 
used to estimate the input rate of diclofenac into the viable skin layers.  This flux was compared to 
that measured across excised porcine skin in conventional diffusion cells.  Both techniques clearly 
demonstrated (a) the superiority in terms of drug delivery from the solution, and (b) that the two 
gels performed similarly.  There was qualitative and, importantly, quantitative agreement between 
the in vitro and in vivo measurements of drug flux into and beyond the viable skin. Evidence is 
therefore presented to support an in vivo – in vitro correlation between methods to assess topical 
drug bioavailability.  The potential value of the stratum corneum tape-stripping technique to 
quantify drug delivery into (epi)dermal and subcutaneous tissue beneath the barrier is 
demonstrated. 
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1 Introduction 
The assessment of drug bioavailability following oral administration is a relatively straightforward 
exercise based on the reasonable assumption that the blood/plasma/serum level profile of the 
active moiety is a reliable surrogate for that at the site of pharmacological action.  As a result, 
establishing the bioequivalence between oral dosage forms generally involves a standard, 
validated protocol (involving in vivo pharmacokinetic studies) that is recognized by regulatory 
authorities all over the world. 
However, in the case of drug products applied to treat local disease either within, or directly below, 
the skin, the measurement of bioavailability – and, by extrapolation, bioequivalence - is more 
complicated (Shah et al., 2015).  Here, the relationship between drug concentration at the site of 
action and that in the systemic compartment is less clear, and the physical measurement of either 
of those concentrations has proved challenging (if not impossible). 
As a result, there is an ongoing effort to develop methodologies with which to evaluate the topical 
bioavailability and bioequivalence of locally-acting dermatological products (Herkenne et al., 2008; 
Lehman et al., 2011; Shah et al., 2015).  This is particularly important for generic topical products 
for which, in most cases, the route to regulatory approval is uniquely via expensive, onerous and 
sometimes quite insensitive clinical outcome studies (Shah et al., 2015).  Several approaches for 
the determination of topical bioavailability and bioequivalence are under investigation, including the 
use of in vitro (human) skin permeation tests, microdialysis (or microperfusion), stratum corneum 
(SC) tape-stripping, and non-invasive optical/spectroscopic techniques (Yacobi et al., 2014; Raney 
et al., 2015; Bodenlenz et al., 2017).  While it seems unlikely that a single, ‘gold-standard’ method 
will be sufficient to uniquely evaluate the bioavailability/bioequivalence of topical products, there is 
a growing recognition that the rational combination of selected techniques can provide a “weight of 
evidence” support for such an assessment.  The choice of tests would depend, for example, on 
factors such as the complexity of the drug product (Chang et al., 2013), as well as the drug’s 
potency (and potential for systemic side effects), and site of action. For each potential approach, a 
robust consideration of practical methodological detail, including the number of replicates/subjects 
required to power a study and appropriate acceptance criteria, will ultimately be required to inform 
regulatory decision-making. 
The aim of the work presented here is to demonstrate a proof-of-concept for the use of 
complementary methods in topical bioavailability/bioequivalence assessment.  Specifically, the SC 
tape-stripping approach in vivo has been used together with in vitro skin permeation to compare 
three marketed diclofenac products, which are approved for different therapeutic indications and 
are not considered bioequivalent.  One formulation, Solaraze® (diclofenac topical gel 3%), is used 
to treat actinic keratosis, while the other two, Voltaren® (diclofenac topical gel 1%) and Pennsaid® 
(diclofenac topical solution 2%), are for pain relief in particular forms of arthritis. 
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SC tape-stripping was the subject of a (now withdrawn) U.S. Food & Drug Administration (FDA) 
guidance (U.S. FDA, 1998) and involves collecting the outermost skin layer (i.e., the SC) using 
adhesive tapes post-application of a drug-containing formulation; subsequently, the drug in the SC 
can be extracted and quantified.  Recently, tape-stripping results, from experiments using modified 
(Parfitt et al., 2011) and improved (N’Dri-Stempfer et al., 2009) protocols, correctly mirrored the 
established bioequivalence of topical anti-fungal creams (the site of action of which, naturally, is 
the SC itself) using clinical end-point studies.  However, there remains an open question as to 
whether SC tape-stripping is a useful (or even meaningful) method to assess the bioavailability and 
bioequivalence of topical drug products which are designed to elicit their effects either within the 
viable epidermis/dermis or, in the case of pain relief induced by diclofenac, for example, in the 
subcutaneous tissue beneath the site of application. 
Consequently, it was decided to compare the results from SC tape-stripping in vivo with data from 
in vitro skin permeation experiments.  Specifically, using the three diclofenac products, 
measurements from the optimized “uptake and clearance” SC tape-stripping protocol (as reported 
in a study with econazole nitrate creams (N’Dri-Stempfer et al., 2009)) were correlated with 
percutaneous fluxes determined in conventional in vitro Franz diffusion cell experiments.  The 
hypothesis tested, therefore, was that drug “clearance” from the SC must reflect ‘input’ into the 
viable skin tissue and beyond, assuming that the SC is the rate-limiting barrier; i.e., into the 
subcutaneous space (or, in the case of an in vitro skin permeation test, the receptor solution of the 
diffusion cell). 
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2 Materials & methods 
2.1. Materials 
The formulations tested (Table 1) were Pennsaid® (diclofenac topical solution 2%) (Mallinckrodt 
Brand Pharmaceuticals, Inc., Staines-upon-Thames, UK), Voltaren® (diclofenac topical gel 1%) 
(Novartis, Basel, Switzerland) and Solaraze® (diclofenac topical gel 3%) (PharmaDerm, Princeton, 
NJ, USA). Diclofenac sodium, solvents and HPLC reagents were from Sigma (Gillingham, UK). 
Table 1: Diclofenac formulations tested. 
Product Code Indication Components 
Pennsaid 2% 
solution 
P 
Osteoarthritis 
of the knee 
Diclofenac sodium, dimethyl sulfoxide, ethanol, water, 
propylene glycol, hydroxypropyl cellulose 
Voltaren 1% gel V Joint pain 
Diclofenac sodium, carbomer homopolymer Type C, cocoyl 
caprylocaprate, fragrance, isopropyl alcohol, mineral oil, 
polyoxyl 20 cetostearyl ether, propylene glycol, water, 
strong ammonia solution 
Solaraze 3% gel S 
Actinic 
keratoses 
Diclofenac sodium, hyaluronate sodium, benzyl alcohol, 
polyethylene glycol monomethyl ether, water 
 
Abdominal pig skin was obtained from a local abattoir, dermatomed (Zimmer®, Hudson, OH, USA), 
to a nominal thickness of 750 µm, frozen within 24 hours of slaughter, and thawed before use. 
2.2. Stratum corneum (SC) tape-stripping experiments 
The protocol was approved by both the Research Ethics Approval Committee for Health at the 
University of Bath, and the FDA’s Research Involving Human Subjects Committee.  The approach 
closely followed a previous in vivo study using econazole (N’Dri-Stempfer et al., 2009); specifically, 
the mass of drug in the SC at one ‘uptake’ and at one ‘clearance’ time point was measured. 
Fourteen healthy volunteers (8 female, 6 male, mean age 28 ± 8 years), who met the study 
inclusion criteria (Table 2), participated in the study having given their informed consent. The test 
site was the volar forearm, at least 5 cm above the wrist and a minimum of 0.5 cm below the bend 
in the arm at the elbow; for volunteers with significant hair growth in the test region, the skin was 
shaved using a new disposable razor at least 24 hours before the study began. 
On the first day of the experiment, both arms were washed (Carex Complete, Cussons, 
Manchester, UK) and dried then left for 1 hour to allow skin hydration to return to normal. This 
procedure ensured that the starting skin condition was, as close as possible, the same for all 
volunteers. Immediately before application of formulations, at a forearm site away from those to be 
treated, two tape-strips were taken to provide drug-free samples of SC to act as controls for the 
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analytical method. In addition, at the skin sites to be treated, the baseline (i.e., intact, unstripped 
skin) transepidermal water loss (TEWL) rate was measured (AquaFlux, Biox Systems Ltd., 
London, UK). 
Six self-adhesive, foam padding frames (Pressure Point Foam Padding, Scholl, Slough, UK), with 
internal dimensions of 1.5 x 5.5 cm, were applied to each arm; as the width of the frame was 0.8 
cm, the minimum distance between the edges of the treated skin sites was 1.6 cm. There were 
duplicate application sites for each product on both arms of each volunteer. Using a cotton bud 
(Johnson & Johnson, Berkshire, UK) to spread the formulation over the treatment area, products P 
and V were applied at 10 mg/cm2, while product S was applied at 20 mg/cm2, reflecting the 
respective recommended use levels. The exact amount applied was determined gravimetrically.  
During the 6-hour uptake period, the sites were not occluded, but were protected by a plastic mesh 
(Ultra-stiff Plastic Canvas, 7 mesh, Darice®, Strongsville, OH, USA) affixed to the skin by Mefix® 
tape (Molnlycke, Lancashire, UK);  the depth of the padding material used for the frame was 
approximately 3 mm, so the mesh was not in contact with the formulation. Volunteers were 
prohibited from bathing during the study or participating in strenuous activity, but otherwise 
pursued their normal lifestyle.  
Table 2: Inclusion criteria for participants. 
Healthy; aged between 18-72 years old 
Male or non-pregnant and non-breastfeeding female 
Any ethnic background 
Willing to provide basic information (i.e., age, height, weight, health, pregnancy status, gender and 
ethnicity and handedness) 
No simultaneous participation in another clinical trial or cosmetic study  
No skin infection, chronic skin disease, hereditary skin disorders or any skin inflammatory conditions 
No excessive pigmentation, tattoos, hair, moles, skin defects, sunburn, or blemishes 
Not a current smoker, and having BMI 30 kg/m2  
No alcohol for 24 hours prior to the start of the study 
Not using any topical drugs at the test site area 
No prescription medication during the period 0-30 days or over-the-counter medication 0-5 days before 
entry to the study (with the exception of oral contraceptives) 
No strenuous exercise during the study period 
No sunbathing or exposure of arms to sun or UV light during participation and/or during the week after 
No previous adverse reaction to diclofenac or to the other ingredients in the formulations tested, to 
medical dressings, or to adhesive tapes 
Length of forearm ≥ 24 cm  
 
After the 6-hour application of the products, formulation remaining on the skin was removed from 
all 12 sites using (a) one dry tissue (Wypall, Kimberly Clarke, Kent, UK), and (b) two 70% isopropyl 
alcohol wipes (Sterets®, Molnlycke, Lancashire, UK). The dry wipe was included when it was 
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observed that, after a 6-hour application of product S, residual solid material (‘flakes’) were visible 
on the treated skin. The cleaned sites on one arm were then designated as “uptake”, while those 
sites on the other were designated as “clearance”. 
2.2.1 Uptake sites, tape-stripped immediately post 6 hours of product application 
Templates (Scotch® Book Tape, 3M, St. Paul, MN, USA), with internal dimensions of 1 x 5 cm, 
were prepared and adhered to each of the treated sites leaving open the skin area to be stripped. 
SC at the 6 uptake sites was then detached via sequential application and removal of adhesive 
tape-strips (1.5 x 6.5 cm, cut from Scotch® Book Tape). To ensure both the comfort of the 
volunteers, and that a significant fraction of the SC was removed by the tape-stripping procedure 
(N’Dri Stempfer et al., 2009), TEWL was measured intermittently during tape-stripping (Kalia et al., 
1996; Kalia et al., 2000) until either (i) the rate of water loss reached 60 g·m-2·h-1, or exceeded 6-
fold the baseline, pre-treatment control value, or (ii) 30 tape-strips had been removed. 
2.2.2 Clearance sites, tape-stripped 23 hours after product application 
Immediately after cleaning, the clearance sites were demarcated using Mefix® tape (Molnlycke, 
Lancashire, UK), without encroaching on the treated areas. The entire volar forearm was then 
covered with light gauze (Boots, Nottingham, UK) to protect the sites overnight. Then, the following 
day, 23 hours after product application (and 17 hours after product removal from skin surface), the 
6 clearance sites were tape-stripped in exactly the same way as performed at the uptake sites.  
2.2.3 Processing of the tape-strips 
All tapes were weighed (Microbalance SE-2F, precision 0.1 µg; Sartorius AG, Goettingen, 
Germany) before and after stripping to determine the mass of SC removed; tapes were first 
discharged of static electricity (R50 discharging bar and ES50 power supply Eltex Elektrostatik 
GmbH, Weil am Rhein, Germany) to facilitate the weighing procedure. Diclofenac was extracted 
from the first two tapes individually but, thereafter, tape-strips from the deeper SC were analysed in 
groups of up to 5 to ensure, as far as possible, that analytical sensitivity was maintained. No tapes 
were discarded. Drug was extracted from the tape-strips with 3 mL of 4:1:1 methanol:hexane:ethyl 
acetate per sample, using sonication for 1 hour at 55°C followed by shaking overnight at 37°C.  
One mL of each sample was evaporated and re-suspended in 1mL of mobile phase and then 
vortexed for 3 seconds. Samples were filtered (0.45 µm nylon membrane, Labhut, Maisemore, UK) 
before analysis by high-performance liquid chromatography (HPLC). 
2.3. In vitro skin permeation test (IVPT) studies 
The formulations were applied to excised abdominal porcine skin mounted in diffusion cells with 
the dermal side in contact with a physiological buffer. The skin was not occluded and the 
formulations were not removed from the skin. The two sets of IVPT studies performed used the 
same receptor solution, which was stirred with a magnetic bar, of phosphate-buffered saline (pH 
7.4) with (set 1) or without (set 2) sodium azide 0.01% w/v.  
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2.3.1. IVPT set 1  
Vertical flow-through cells (Laboratory Glass Apparatus, Berkeley, CA, USA) with an exposed skin 
area of 3.14 cm2 were used. Formulations were applied using the flat base of a 2 mL glass vial, 
and the mass of product applied was determined by simple weight difference. Four replicates were 
performed per formulation using skin from donor ‘Pig A’. The receptor solution volume was ~7.7 
mL, and was thermostatted via recirculating water maintained at 37°C. The receptor solution flow 
rate was ~1 mL/h (the average for each cell was measured) and samples were collected on a 
fraction collector every 4 hours.  
2.3.2. IVPT set 2  
Static, Franz cells (Permegear, Hellertown, PA, USA) with an exposed skin area of 2.01 cm2 and a 
receptor volume of ~7.4 mL were used. Formulations were applied using a cotton bud (i.e., similar 
to the in vivo tape-stripping experiments), and the mass of product applied was again determined 
by weight difference. Eight replicates were performed per formulation, 4 using skin from donor ‘Pig 
B’, and 4 with skin from donor ‘Pig C’. Throughout the experiment, the diffusion cells remained in 
an oven at 32°C and 40% relative humidity, except for brief excursions when the receptor solution 
was sampled (1 mL) at 6, 8, 10, 12, 23, 26 and 30 hours. The concentrations of diclofenac 
measured in the receptor phase samples were never more than 2 µg/mL, i.e., far below the 
aqueous solubility of the drug at pH 7.4 (which is, in fact, about 103-fold higher; Maitani et al., 
1993), therefore ensuring that sink conditions were maintained throughout the experiment. 
2.4. High-performance liquid chromatography (HPLC) 
Diclofenac was quantified by HPLC (Summit, Dionex, Camberley, UK) with UV detection (284 nm). 
A mobile phase of 65:35 methanol:0.2% triethylamine (adjusted to pH 2.85 with phosphoric acid) 
was pumped (1mL/min) through a 250 x 4.6 mm Kinetex C18 column (Phenomenex, Macclesfield, 
UK). Retention time was ~10 minutes. Injection volume was 50 µL; limits of quantification and 
detection were 0.03 and 0.01 µg/mL, respectively.  
2.5. Data analysis  
2.5.1. SC tape-stripping  
The thickness of SC removed on each tape was calculated from the weight and area sampled, 
assuming a tissue density of 1 g/cm3 (Anderson & Cassidy, 1973). 
At both uptake and clearance, the thickness of stratum corneum removed, the number of tapes 
used, and final TEWL value measured were compared across the 3 products using a repeated 
measures ANOVA followed by Bonferroni post-tests. In addition, for each product, the same 
parameters were compared using a paired t-test. The geometric mean of the mass of drug 
extracted (in the two duplicate sites) from the tape-strips was calculated for each volunteer; these 
values were then averaged (arithmetic mean) across n = 14, for each time point and each product. 
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The average flux of drug from the SC into the underlying tissue between the uptake and clearance 
time points (Jin vivo) was calculated for each formulation and for each volunteer:  
Jin vivo = (MUp,6h/A – MCl,23h/A)/Δt    (Eq. 1) 
where MUp,6h is mass of drug in the SC at 6 hours after drug application, MCl,23h is mass of drug in 
the SC at 23 hours, A is the sampled skin area, and Δt is the duration of the clearance period, i.e., 
17 hours. 
Further, assuming a first-order clearance of the drug from the SC, then the associated rate 
constant, k, is given by: 
k = -ln(MCl,23h/MUp,6h)/Δt = -ln(MCl,23h/MUp,6h)/(17 h)   (Eq. 2) 
Note that k is a rate constant averaged over the clearance period of 17 h.  It may not necessarily 
have the same value for shorter or longer periods of clearance.  
2.5.2. IVPT set 1 
The flux of drug into the receptor solution from the skin (Jn) during the nth sampling time interval 
was calculated using the following equation (Touraille et al., 2005): 
Jn =
QR
VR
[
MS,n/A
VS,n VR+exp⁡(−tnQR VR)∙{1−exp⁡(VS,n VR)⁄ }⁄⁄
]   (Eq. 3) 
where: A = treated skin area, MS,n = mass of drug in the nth sample vial, tn is the time between drug 
application and the end of the nth sampling interval, QR = volumetric perfusion rate of receptor 
solution, VR = volume of receptor chamber, and VS,n = volume of the nth sample.  The cumulative 
mass of drug into the receptor solution at time tm was calculated by numerical integration of Jn 
using the trapezoid rule (where J0 is assumed to be zero): 
MR,m
A
=∑
(tn-tn-1)
2
m
n=1 (Jn+Jn-1)   (Eq. 4) 
The apparent average flux of drug into the receptor chamber between 8 and 24 hours (Jin vitro) was 
then calculated for each cell:  
Jin vitro = (MR,24h/A – MR,8h/A)/t = (MR,24h/A – MR,8h/A)/16h   (Eq. 5) 
where MR,8h and MR,24h are the cumulative mass of drug permeated into the receptor chamber after 
8 hours and 24 hours, respectively. 
2.5.3. IVPT set 2 
The amount of drug permeated at each time interval was calculated from the measured 
concentration in the receptor solution, taking into account that removed in each sampling. The flux 
of drug into the receptor chamber between 6 and 23 hours was then calculated for each cell:  
Jin vitro = (MR,23h/A – MR,6h/A)/17h   (Eq. 6) 
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Data obtained using skin from the two pig ‘donors’ were pooled, and Jin vitro, MR,6h and MR,23h were 
then compared across the 3 products using a one-way ANOVA followed by Bonferroni post-tests. 
Statistical significance was again set at p < 0.05.  
2.5.4. Statistics 
The cumulative mass into the receptor (MR), and the flux (J), for the SC tape-stripping and IVPT 
experiments, as well as the mass in the SC for the in vivo tape-stripping, were compared across 
the 3 products using a repeated measures ANOVA followed by Bonferroni post-tests. Also, for 
each product in the SC tape stripping experiment, MUp,6h was compared to MCl,23h using a paired t-
test. In all the comparisons undertaken, statistical significance was set at p < 0.05. Reported 
confidence intervals were calculated using the Student’s T-distribution for the sample size and the 
sample standard deviation.   
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3 RESULTS 
3.1. SC tape-stripping experiments 
This component of the study was performed in 14 healthy volunteers and assessed the method’s 
ability to distinguish between drug products that were not expected to be bioequivalent. No 
adverse events were recorded, and all volunteers completed the study. The clinically relevant 
doses of formulation applied were (arithmetic mean ± standard deviation) 9.9 ± 0.7, 10.3 ± 0.6 and 
19.4 ± 1.6 mg/cm2 for products P, V and S, respectively. Table 3 summarizes information about the 
collection of SC from the treated sites at both uptake and clearance times. An adequate fraction of 
the SC was removed (total SC thickness on the ventral forearm has been reported to be 10.9 ± 3.5 
µm (Kalia et al., 2000)).  
Table 3: SC collection from the treated sites – numbers of tapes used, thickness of SC removed 
and final TEWL measured when tape-stripping stopped. Arithmetic mean of within-subject 
duplicates ± standard deviation across all 14 subjects. Pairs of superscript letters indicate 
statistical differences (p < 0.05). 
Product P V S 
Uptake Clearance Uptake Clearance Uptake Clearance 
Number of 
tapes used 
17 ± 10a,b 23 ± 9c,d 30 ± 0a 30 ± 0c 30 ± 1b 30 ± 0d 
SC thickness 
removed (µm) 
7.1 ± 3.9e 7.2 ± 3.2f,g 5.4 ± 2.3e 5.1 ± 2.4f 5.9 ± 3.3 4.8 ± 2.3g 
Final TEWL*  
(g·m-2·h-1) 
63.1 ± 21.1h,i 51.8 ± 14.0j,k 32.2 ± 19.5h 24.5 ± 16.2j 27.8 ± 13.6i 21.5 ± 9.8k 
*Mean baseline TEWL was measured to be 11.6 ± 3.5 (g·m-2·h-1).  There was no significant difference 
between the values determined at the three sets of sites treated with the three different products (i.e., SC 
integrity pre-treatment was consistent at all skin sites used). 
A clear formulation-specific effect on SC removal was observed. More SC was detached, using 
fewer tapes, from sites treated with product P relative to those exposed to products V or S. At sites 
to which product P had been applied, it was frequently observed that, within discrete parts of the 
sampled area, several layers of corneocytes appeared to have been removed with a single tape (a 
phenomenon that has been previously reported with an acyclovir formulation (Russell & Guy, 
2012)). This effect was seen at skin sites used for both uptake and clearance measurements; i.e., 
independent of whether tape-stripping was performed immediately post-formulation removal or 17 
hours later.  
Diclofenac was easily quantified in the SC, with less than 1% of the samples analysed having 
amounts below the limit of quantitation. Figure 1 shows the total drug mass recovered from the SC 
for each volunteer at uptake and clearance times. Some variability between duplicate 
measurements (2 sites with same product at the same time point in the same person) was 
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observed, and may be due to differences between the skin sites, or variability in application of the 
formulations, or variability in the efficiency of removing unabsorbed formulation at the end of the 
uptake period. Inter-subject variability in dermal drug absorption was observed as expected, 
highlighting the importance of comparing products within-subject to increase the method’s 
sensitivity to detect differences between products. 
  
Figure 1: Mass of diclofenac recovered from each skin site, with duplicate determinations 
performed for each product and each time point for all subjects (n = 14). Horizontal lines are the 
geometric means of the 2 duplicate values (shown by the symbols).   
There was a clear distinction, as seen in Figure 1 (note the different y-axis scales) and Table 4, in 
the amounts of diclofenac taken up into the SC from the 3 products.  The mass of drug recovered 
from the SC was significantly greater (p < 0.05) after application of product P than that post-
treatment with either product V or product S, at both uptake and clearance. However, the results 
for products V and S were much closer. 
For all products, the mass of drug in the SC at uptake was significantly higher than that at 
clearance, indicating that measurable transfer of diclofenac into the viable skin (and presumably 
A B C D E F G H I J K L M N
0.0
2.5
5.0
7.5
10.0
Product V
Subject
D
ru
g
 in
 S
C
 (
u
g
/c
m
2
)
A B C D E F G H I J K L M N
0
5
10
15
20
Product S
Subject
D
ru
g
 i
n
 S
C
 (
u
g
/c
m
2
)
A B C D E F G H I J K L M N
0
20
40
60
80
Product P
Subject
D
ru
g
 in
 S
C
 (
u
g
/c
m
2
)
A B C D E F G H I J K L M N
0.0
2.5
5.0
7.5
10.0
Subject
D
ru
g
 i
n
 S
C
 (
u
g
/c
m
2
)
A B C D E F G H I J K L M N
0
5
10
15
20
Subject
D
ru
g
 i
n
 S
C
 (
u
g
/c
m
2
)
A B C D E F G H I J K L M N
0
20
40
60
80
Subject
D
ru
g
 i
n
 S
C
 (
u
g
/c
m
2
)
Uptake Clearance
14 
 
beyond) had occurred. The average, relative depletion of drug from the SC during the clearance 
phase (33%, 31% and 33%, respectively for products P, V and S) was similar to that observed 
previously for econazole (N-Dri’Stempfer et al., 2009); for 26 of the 42 pairs of values, ≥25% of the 
drug in the SC at uptake was cleared over the next 17 hours.  
Table 4: Mass of diclofenac recovered from the SC after uptake and clearance (MUp,6h and MCl,23h, 
respectively), the deduced drug flux from the SC into the underlying viable tissue during the 
clearance period (Jin vivo), and the first-order rate constant (k) describing clearance from the SC. 
Arithmetic mean ± 90% confidence interval (n = 14). Pairs of superscript letters indicate statistical 
difference. 
Product P V S 
MUp,6h/A (µg·cm-2) 36 ± 7.7a,b,g 5.5 ± 1.0a,h 6.4 ± 1.5b,i 
MCl,23h/A (µg·cm-2) 24 ± 6.2c,d,g 3.8 ± 1.3c,h 4.3 ± 1.4d,i 
Jin vivo (ng·h-1·cm-2) 694 ± 312e,f 97 ± 59e 128 ± 93f 
k (h-1) 0.030 ± 0.020 0.036 ± 0.019 0.033 ± 0.022 
Figure 2 presents the drug concentration versus SC depth profiles post-application of the 3 
products at uptake and clearance.  In this case the y-axis scales are the same for the three 
products and the profiles again illustrate clearly the enhanced delivery of diclofenac from product P 
relative to the other two formulations.  Visually inspecting profiles like these serves as a useful 
check on the quality of the results obtained, for example, to detect very clear outliers in the data or 
(if the profile appears ‘truncated’) to indicate insufficient sampling of drug from the deeper SC. 
Although there is no reason to consider the three products evaluated in this study as bioequivalent, 
it is possible to illustrate how the results obtained may be used to address this issue.  Table 5 
shows the results of a bioequivalence assessment of the 3 products. For each volunteer, the ratio 
of the mass of diclofenac in the SC (at uptake and clearance) was calculated between pairs of 
products. The log transformed ratios were then averaged across all participants and the 90% 
confidence interval calculated (US FDA, 2001). The average and 90% confidence intervals of the 
ratios (i.e., the inverse log transformation of the average and confidence intervals of the log 
transformed ratios) are in Table 5. Typically, if the confidence intervals fall within the range of 0.8 
to 1.25, the two products are considered bioequivalent.  As expected from the high-level evaluation 
of the data presented thus far, the results of this analysis are (a) that product P is conclusively 
inequivalent to both products S and V, and (b) that products S and V fail the equivalency test at the 
lower end of the range. 
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Table 5: “Bioequivalence” assessment between the 3 products. Values are inversed logs of the 
{log[mean ratio]} for product pairs (lower - upper 90% confidence interval) for n = 14 subjects. 
Comparison P to V P to S V to S 
Uptake 6.27 (5.10 - 7.71) 5.69 (4.47 - 7.25) 0.91 (0.74 - 1.12) 
Clearance 6.94 (5.16 - 9.32) 6.06 (4.82 - 7.62) 0.87 (0.70 - 1.09) 
  
 
Figure 2: Diclofenac concentration versus SC depth profiles following application of 3 drug 
products and assessed after uptake and clearance; raw data (not averages of duplicate values) are 
plotted. Data from tape-strips with a very low mass of SC (<0.012 mg per group) have not been 
plotted. When tape-strips were grouped for drug analysis, the SC depth plotted on the x-axis 
represents the midpoint for that sample.  
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While this approach can assess the relative bioavailability of the drug from different products, the 
relevance of doing so for diclofenac, the site of action of which is clearly not the SC, may be 
questioned.  For this reason, the uptake and clearance amounts of the drug in the SC were used to 
deduce an average flux (Jin vivo) during the 17 hours that elapsed between the two measurements 
(see Table 4).  Although these values were associated with relatively large standard deviations 
(primarily because, for 3 out of 14 cases for each product, the observed difference between MUp,6h 
and MCl,23h was indistinguishable from zero), the conclusion drawn from the results is clear: namely, 
that product P delivered significantly more drug both into and through the SC than either of 
products V and S; the performance of the latter two products, however (again, both in terms of 
diclofenac delivery into and across the SC), was not significantly different.  
It is also noteworthy that, while the flux through the skin is much larger from product P than from 
products V and S, the estimated clearance rate constants (recalling that flux is proportional to rate 
constant multiplied by SC concentration) are not statistically different for the 3 products.  This is 
completely consistent with the higher flux from product P resulting from the greater amount of 
diclofenac in the SC at the end of the uptake period (and not, for example, being due to a larger 
diffusivity).   
3.2. IVPT experiments  
The IVPT results from “set 1” and “set 2” experiments are summarized in Figure 3. 
3.2.1. IVPT set 1 
The clinically relevant doses of formulation applied were (arithmetic mean ± standard deviation) 
10.6 ± 1.1, 10.3 ± 0.6 and 19.7 ± 0.4 mg/cm2 for products P, V and S, respectively.  The cumulative 
penetration of diclofenac into the receptor chamber of the diffusion cell after 8 and 24 hours, and 
the deduced flux across the skin from the 3 formulations are in Table 6.  Statistical analysis of the 
results was entirely consistent with the in vivo data discussed above: each of the metrics, MR,8h, 
MR,24h and Jin vitro, was significantly larger for product P than both products V and S, which were 
statistically indistinguishable.  Panel (d) of Figure 3, which shows the permeation fluxes of 
diclofenac from the three formulations as a function of time, clearly reinforces these observations. 
The steady increase in flux over the 32-h experiment for products V and S differed from that for 
product P, which exhibited a maximum at about 16 h followed by a slow decline. The significant 
presence of DMSO in the composition of product P is undoubtedly the major reason behind the 
distinct behaviour of this formulation. 
3.2.2. IVPT set 2 
The doses of formulation applied were (arithmetic mean ± standard deviation) 10.0 ± 0.5, 9.4 ± 0.3 
and 20.2 ± 1.1 mg/cm2 for products P, V and S, respectively. This series of experiments was 
performed using skin from two additional pigs.  The cumulative penetration of diclofenac into the 
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receptor chamber of the diffusion cell after 6 and 23 hours, and the deduced flux across the skin 
from the 3 formulations are in Table 7; individual results from the measurements made with skin 
from the different ‘donors’ and the combined dataset are shown.  
 
 
Figure 3:  Panels (a), (b) and (c) show cumulative diclofenac permeation from 3 topical products, 
as a function of time across porcine skin in vitro, from the “set 1” experiments (skin from pig A, 
circles) and the “set 2” study (skin from pigs B (squares) and C (triangles)).  Panel (d) - diclofenac 
fluxes measured in the “set 1” experiments using flow-through diffusion cells.  All data shown are 
the arithmetic mean and 90% confidence interval (n = 4 for each case). 
Noticeable variability in drug permeation across skin from the different pigs was seen for products 
V and S; in contrast, for product P, excellent agreement for the two skin sources was observed.  
These observations could be related to a reduction of the skin barrier by product P that does not 
occur for products V and S. Nevertheless, despite this variability, and the procedural and data 
analytical differences used in the two sets of IVPT experiments (different diffusion cells, 
thermostatting method, sample times chosen for comparison), the results in “set 2” mirror exactly 
those seen in “set 1” and are consistent once more with those observed in the in vivo SC tape-
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stripping study: each of the metrics, MR,6h, MR,23h and Jin vitro for product P was significantly greater 
than those for products V and S, which were statistically indistinguishable. 
Table 6: Results from the in vitro penetration test “set 1” experiments. The data (arithmetic mean ± 
90% confidence (n = 4)) were obtained using skin from pig A in flow-through diffusion cells. Pairs 
of superscript letters indicate statistical difference. 
Product P V S 
MR,8h/A (µg·cm-2) 0.39 ± 0.14a,b 0.05 ± 0.09a 0.09 ± 0.14b 
MR,24h/A (µg·cm-2) 12 ±  5.8c,d 0.90 ± 0.57c 1.9 ± 1.64d 
Jin vitro (ng·h-1·cm-2) 737 ± 357e,f 53 ± 30e 110 ± 94f 
Table 7: Results from the in vitro permeation test “set 2” experiments. The data (arithmetic mean ± 
90% confidence) were obtained using skin from pigs B (n = 4) and C (n = 4) in static diffusion cells. 
Pairs of superscript letters indicate statistical difference; n.d. = not detected. Values in parenthesis 
for product S excludes 2 samples for which no measureable permeation was observed. 
Product Skin (n) MR,6h/A (µg·cm-2) MR,23h/A (µg·cm-2) Jin vitro  (ng·h-1·cm-2) 
P 
Pig B (4) 0.45 ± 0.11 5.1 ± 1.7 274 ± 95 
Pig C (4) 0.16 ± 0.25 4.6 ± 3.5 260 ± 193 
Combined (8) 0.30 ± 0.15a,b 4.8 ± 1.5c,d 267 ± 80e,f 
V 
Pig B (4) 0.15 ±  0.16 1.0 ± 0.78 51 ± 37 
Pig C (4) <LOQ 0.33 ± 0.29 19 ± 16 
Combined (8) 0.08 ± 0.08a 0.67 ± 0.39c 35 ± 19e 
S 
Pig B (4) 0.07 ± 0.11 0.75 ±  0.36 40 ± 15 
Pig C (4) n.d. 
0.07 ± 0.08 
(0.13 ± 0.02, n = 2) 
4.3 ± 4.5 
(7.5 ± 1.2, n = 2) 
Combined (8) 
0.04 ± 0.05b  
(0.05  0.07, n = 6) 
0.41 ± 0.28d  
(0.54  0.33, n = 6) 
26 ± 17f  
(29  16, n = 6) 
 
3.3. In vivo – in vitro comparison 
The in vivo and the in vitro experiments performed both permit an estimation of the flux of 
diclofenac into the viable skin tissue (and beyond) from the 3 products examined.  Figure 4 
graphically presents a summary of the results obtained.  Importantly, the overall message 
delivered by the data was consistent, namely, the enhanced drug delivery from product P 
compared to the other two formulations, and the similarity between the V and S products.  In 
addition, the fluxes deduced from the two distinct experimental approaches are generally 
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consistent, despite the different skin sources used and the variations in the in vitro protocols 
adopted. 
 
 
Figure 4: Comparison of Jin vivo and Jin vitro deduced from the SC tape-stripping study in human 
volunteers (n = 14) and the two sets of Franz diffusion cell measurements (n = 4 for set 1, n = 8 for 
set 2) using excised porcine skin (arithmetic mean + 90% confidence interval). 
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4 Discussion  
The research described here has compared two methods, stratum corneum (SC) tape-stripping in 
vivo in man and in vitro skin permeation (using porcine tissue), as surrogate approaches with 
which to assess and compare a drug’s topical bioavailability following application in different 
products.  The experiments were undertaken using 3 marketed formulations containing diclofenac 
as the active pharmaceutical ingredient, with sites of action either in the viable skin below the SC 
barrier or deeper within the subcutaneous tissue.  An important issue to address, therefore, was 
whether SC tape-stripping (which has already been shown capable of accurately evaluating the 
local bioavailability of anti-fungal drugs which act on or in the SC (N’Dri-Stempfer et al., 2009; 
Parfitt et al., 2011)) is able to provide a suitable metric to characterize the rate and/or extent of 
drug absorption to skin tissues beneath the SC.   A further aim was to compare the in vivo results 
to those from the IVPT approach to examine whether a correlation and/or synergy might exist 
between the two methodologies. 
SC tape-stripping in vivo has several advantages, including: (a) it can be performed in a minimally 
invasive way, in man; (b) the experiment is conducted with a fully functioning cutaneous 
microcirculation in operation that permits drug clearance from the skin to take place unimpeded; (c) 
uptake of drug into the SC can be assessed after much shorter time periods than are typically 
needed when using in vitro techniques; and (d) tissue viability throughout the experiment is 
assured.   
Equally, the use of Franz diffusion cells in vitro with excised human (or other animal model) skin 
provides benefits that SC tape-stripping does not.  For example, a dermal pharmacokinetic profile 
is available via frequent sampling of the receptor solution over the duration of an IVPT experiment, 
and is much less onerous, and far more practical, than performing tape-stripping at multiple time 
points; an IVPT experiment permits a direct evaluation of drug flux into and through the viable skin; 
and it is relatively straightforward, if required, to assay the drug levels in the epidermis/dermis at 
the end of the permeation experiment. 
The SC tape-stripping experiments undertaken in this work provided three metrics with which to 
compare the 3 products considered: (i) the mass of drug in the SC after a 6-hour uptake period, (ii) 
the mass of drug in the SC after a subsequent 17-hour clearance period, and (iii) from the 
difference between these two values (per unit time), an estimate of the input rate or flux of the drug 
into the viable skin below the SC. Regardless of the metric chosen, the results were clear and 
statistically significant: the uptake and permeation of diclofenac from product P was much greater 
than that from either product S or product V, whereas the apparent bioavailability of the drug from 
products S and V was similar.  
The higher performance of product P is most likely due to the presence (>40% w/w) of dimethyl 
sulfoxide (DMSO) in the formulation; neither product V nor product S contains this excipient. 
21 
 
DMSO is a well-known skin penetration enhancer, and is believed to exert its effect by altering 
protein (i.e., keratin) conformation and/or perturbation of intercellular lipid organization in the SC 
(Williams & Barry, 2012). DMSO itself is rapidly taken up into the SC and can also, through its 
excellent solvation properties, facilitate drug partitioning into the barrier (Williams & Barry, 2012).  
The similarity in the deduced clearance rate constants (Table 4), from the SC tape-stripping 
experiments using the three different products, suggests that the latter mechanism of DMSO 
enhancement is probably the dominant one for product P (although the easier removal of SC post-
application of this product, and the extent to which TEWL was increased (Table 3), also suggest 
that some degree of barrier disruption was provoked).   
Product P also produced a formulation-specific effect on SC collection (i.e., fewer tape-strips were 
needed to remove a larger fraction of the barrier (Table 3)) confirming that using a fixed number of 
tape-strips does not guarantee removal of a consistent mass of SC (Tsai et al., 1991; Lademann et 
al., 2009), and that the amount of SC sampled should be quantified by a suitable method. 
Nevertheless, it should be pointed out that differential formulation effects on SC collection are less 
likely to occur when assessing the bioequivalence of a generic product that is Q1 and Q2 
equivalent to the reference listed drug. 
In the in vivo experiment, the 3 products were assessed using duplicate measurements at two time 
points, resulting in 12 treatment sites per participant, as used in an earlier study comparing 3 
econazole creams (N’Dri-Stempfer et al., 2009). The arrangement, though, is flexible such that, if 
only two products were being compared, for example, additional replicate sites could be included. 
Replicate measurements are advantageous because they yield values closer to the ‘true’ 
population mean, and also provide information about within-subject variability. This is key when 
deciding, for instance, the appropriate bioequivalence acceptance criteria to use (e.g., 0.8-1.25 
versus 0.75-1.33), and/or the appropriate number of participants required to power the study. 
The metrics chosen to analyze the IVPT experiments were (a) the cumulative mass of diclofenac 
that had permeated to the receptor solution after 6 or 8 hours, (b) the cumulative mass of 
diclofenac that had permeated to the receptor solution after 23 or 24 hours, and (c) the average 
flux of the drug across the skin either during the period 6-23 hours or 8-24 hours (determined by 
the difference between the cumulative amounts divided by the time elapsed between those 
measurements).  Statistical inspection of the results revealed exactly the same conclusions as 
deduced from the in vivo experiments: the topical delivery of diclofenac from product P was 
significantly greater than that from either product S or product V, whereas the permeation of the 
drug showed no difference from products S and V. 
Porcine skin was used in the IVPT experiments for two reasons: first, the limited availability of 
human skin and, second, because it is considered to be a reliable model for the human barrier 
(Sekkat & Guy, 2001).  However, the results obtained from the three pigs which provided skin for 
this work demonstrate that the variability seen in human IVPT studies is also duplicated when 
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porcine skin is used. It follows that, as has become common practice (Franz et al 2009), there is an 
obvious requirement to carefully match the tissue used in IVPT studies across formulations and to 
ensure that replicate experiments are performed with skin from multiple donors. 
Nonetheless, the fluxes of diclofenac into the viable skin tissue (and beyond) from the 3 products, 
as determined both in vivo and in vitro, were in reasonable qualitative and quantitative agreement, 
given both the stark difference between the two types of protocol used (SC tape-stripping versus 
IVPT), and the differences between the subsets of IVPT methods employed. It seems reasonable 
to suggest, therefore, that in vivo – in vitro correlation in topical bioavailability assessment is an 
achievable goal, and that the judicious selection of complementary tools for measuring the rate and 
extent of skin uptake, permeation and clearance offers a viable, surrogate strategy to characterize 
and optimize formulation performance. 
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5 Conclusion 
SC tape-stripping in vivo in man and in vitro skin permeation experiments using porcine skin have 
been used to assess the topical bioavailability of diclofenac following application of the drug in 
three approved and commercialized products. The results from both approaches clearly 
differentiate one formulation, which delivers significantly more of the active pharmaceutical 
ingredient, and also reveal that the other two formulations are similar in their performance. There is 
qualitative and (reasonable) quantitative agreement between the in vivo and in vitro methods and 
this correlation provides evidence that the SC tape-stripping technique can also be used to 
generate information pertinent to the bioavailability of topical drugs whose site of action lies below 
the skin barrier.  
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